Ocular Therapeutix (OCUL) Profit After Tax (2013 - 2026)
Ocular Therapeutix's (OCUL) quarterly Profit After Tax came in at -$88.6 million in Q1 2026, down 38.34% year-on-year from -$143.7 million in Q1 2025, and down 37.06% quarter-over-quarter from -$64.7 million in Q4 2025.
Ocular Therapeutix (OCUL) Profit After Tax (2013 - 2026) Analysis & Trends
Ocular Therapeutix's Profit After Tax history runs 14 years deep, the most recent figure standing at -$88.6 million for Q1 2026.
- On a quarterly basis, Profit After Tax fell 38.34% year-over-year to -$88.6 million in Q1 2026; TTM through Mar 2026 was -$290.5 million, a 50.74% decrease from a year earlier, with the FY2025 full-year figure at -$265.9 million, down 37.43% from the prior year.
- Profit After Tax slipped to -$88.6 million in Q1 2026 per OCUL's latest filing, from -$64.7 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$516000.0 in Q3 2023 and bottomed at -$88.6 million in Q1 2026.
- The 5-year median for Profit After Tax is -$36.5 million (2024), against an average of -$41.2 million.
- Across the five-year window, Profit After Tax jumped 97.87% in 2023 and plunged 6972.29% in 2024, its largest moves.
- Year by year, Profit After Tax stood at -$15.5 million in 2022, then plunged by 88.01% to -$29.2 million in 2023, then slumped by 65.6% to -$48.4 million in 2024, then sank by 33.62% to -$64.7 million in 2025, then tumbled by 37.06% to -$88.6 million in 2026.
- Per Business Quant, the three latest OCUL Profit After Tax figures stand at -$88.6 million (Q1 2026), -$64.7 million (Q4 2025), and -$69.4 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Ocular Therapeutix | 1.93 Bn | 1.93 Bn | 9.46 Mn | -88.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -88.61 Mn |
| Dec 31, 2025 | -64.65 Mn |
| Sep 30, 2025 | -69.42 Mn |
| Jun 30, 2025 | -67.81 Mn |
| Mar 31, 2025 | -64.05 Mn |
| Dec 31, 2024 | -48.39 Mn |
| Sep 30, 2024 | -36.49 Mn |
| Jun 30, 2024 | -43.78 Mn |
| Mar 31, 2024 | -64.85 Mn |
| Dec 31, 2023 | -29.22 Mn |
| Sep 30, 2023 | -516,000.00 |
| Jun 30, 2023 | -20.68 Mn |
| Mar 31, 2023 | -30.32 Mn |
| Dec 31, 2022 | -15.54 Mn |
| Sep 30, 2022 | -24.19 Mn |
| Jun 30, 2022 | -18.77 Mn |
| Mar 31, 2022 | -12.54 Mn |
| Dec 31, 2021 | -3.85 Mn |
| Sep 30, 2021 | 2.66 Mn |
| Jun 30, 2021 | -8.48 Mn |